Celgene Corporation and its employees are working relentlessly to provide solutions for unmet medical needs in cancer and debilitating inflammatory diseases.

There are more than 200 ongoing clinical trials at major medical centres worldwide using innovative compounds from Celgene.

These investigational compounds are being actively studied in clinical trials for patients with incurable haematological and solid tumour cancers, including:

• multiple myeloma
• myelodysplastic syndromes
• chronic lymphocytic leukemia
• non-Hodgkins lymphoma
• glioblastoma
• ovarian cancer
• pancreatic cancer
• prostate cancer

By utilizing the latest advances in molecular and cellular research to develop novel therapies that target the mechanisms of disease at their source, Celgene is making potentially life-saving treatments a reality for the millions of patients around the world fighting cancer and other debilitating diseases.